MT7117 Study
Are You Eligible?This study is testing a potential new treatment for EPP or XLP that increases melanin in the skin, which protects you from sunlight.
Research Objectives
Status
Recruitment
Study location
Study type
Patient group
Industry sponsor
About this clinical trial
Erythropoietic Protoporphyria (referred to as “EPP”) or X-Linked Protoporphyria (referred to as “XLP”) are characterized by the accumulation of a molecule named protoporphyrin in the body, which leads to pain when the skin is exposed to sunlight. The purpose of this trial is to investigate whether an experimental drug called MT-7117 (Dersimelagon) is effective and well tolerated in reducing the severity of symptoms of EPP or XLP.
Lead investigator
- Prof David Coman
Clinical trial coordinator
- Venita Bali
Technical title
A Phase 3, Multicenter, Open-Label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)
Register your interest
If you would like more information about this clinical trial, please complete the contact form below.